UNSPSC 51343309: Viroxime

This classification denotes an antiviral agent with the molecular formula (C17H18N4O3S)2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I5V34WG2BE, more generally known as viroxime. European Medicines Agency schedules viroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00082MIG. The term VIROXIME is an International Non-Proprietary Name or INN. VIROXIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule viroxime under HS 29350090 and SITC 51580. As of Q4 2014, VIROXIME remains the US FDA Preferred Term for this commodity. SMILES: CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C(=NO)C3=CC=CC=C3)N=C1N.

UNSPSC 51343309 Viroxime is a Commodity code that does not show relevant recent state and local procurement activity. The two opportunities tagged under this code — a completed pharmaceutical warehouse piggyback award for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets, and a Seminole County, Florida bid for Naloxone and drug deactivation systems — neither involves Viroxime nor reflects the scope of the code's nominal classification. The Illinois Department of Public Health award to Chartwell Rx LLC was for antibiotics supplied through a consortium piggyback mechanism, and the Seminole County procurement targets opioid-reversal agents and drug disposal systems for community health delivery. These do not represent active demand for the specific pharmaceutical product this code designates.

Without recent opportunities actually soliciting Viroxime under this code, the geographic and issuing-body patterns cannot be characterized from current market activity. State and local governments may hold standing contracts or use cooperative purchasing vehicles for this product, but the current opportunity record does not surface open solicitations or active buying signals under UNSPSC 51343309. A vendor evaluating this code should confirm whether state and local agencies are sourcing Viroxime through alternative procurement channels, such as state pharmaceutical consortia, GSA-equivalent cooperative agreements, or direct awards not yet visible in the public opportunity stream.